Clinical Trials Logo

Analgesia, Obstetrical clinical trials

View clinical trials related to Analgesia, Obstetrical.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05099055 Completed - Analgesia Clinical Trials

Dexmedetomine as Adjuvant for Spinal Anesthesia in Elective Cesarian Sections : a Pilot Study

Start date: March 15, 2022
Phase: Phase 3
Study type: Interventional

The proposed pilot study is a prospective, randomized, controlled, double-blind, single-center pilot study.The aim of this pilot project is to evaluate the feasibility of a phase III study on the use of dexmedetomidine in intrathecal in the context of elective cesarean section. The target population for the study will be adult pregnant women undergoing elective cesarean section under spinal anesthesia. This study will be carried out at a single site, the CHU Sainte-Justine as part of a research internship as part of the anesthesiology residency program at the University of Montreal.

NCT ID: NCT03574441 Completed - Clinical trials for Analgesia, Obstetrical

Intrapartum Epidural Catheter Displacement: Dressing Methods

Start date: December 4, 2017
Phase: N/A
Study type: Interventional

Failure of labor epidural is a well-recognized situation in obstetric anesthesia practice. Incidence of epidural failure was shown to be 12% in a retrospective analysis of 19,259 deliveries. Epidural migration has been documented in both the obstetric and non-obstetric settings. It has been argued that prevention of epidural displacement is a potential remedy to at least part of the incomplete or failed epidurals in obstetrics. Purpose: The investigators propose this study to prospectively evaluate the efficacy of the three types of epidural catheter dressings that are currently in use in clinical practice, in terms of catheter migration, taking into consideration the influence of body mass index on this variable.

NCT ID: NCT03065530 Completed - Postoperative Pain Clinical Trials

Intravenous Dexmedetomidine for Cesarean Section

Start date: February 7, 2017
Phase: Phase 4
Study type: Interventional

Nervous, anxiety, fear and other psychological reactions always appears in parturients during cesarean section. This study intends to investigate the effectiveness and safety of dexmedetomidine combined with butorphanol tartrate for postoperative analgesia and breastfeeding after caesarean section.

NCT ID: NCT02920489 Completed - Labor Pain Clinical Trials

Individualized Timing of Analgesia and Effectiveness of Labor Analgesia

Start date: August 2016
Phase: N/A
Study type: Interventional

Neuraxial analgesia is the gold standard to relieve labor pain. A recent "Practice guidelines for obstetric anesthesia" suggests that neuraxial analgesia should be provided in the early stage of labor (cervical dilation < 5 cm) or on a individualized basis. The purpose of this randomized controlled trial is to investigate whether neuraxial labor analgesia administered on an individualized basis can improve analgesia quality and maternal satisfaction.

NCT ID: NCT02823418 Completed - Clinical trials for Depression, Postpartum

Neuraxial Labor Analgesia and the Incidence of Postpartum Depression

Start date: August 1, 2014
Phase:
Study type: Observational [Patient Registry]

Postpartum depression (PPD) affects approximately 15% of women during the first year after giving birth, and is common across cultures. The etiology of postpartum depression is not totally clear. The severe pain experienced during childbirth was reported to be associated with the development of postpartum depression. The purpose of the present study is to evaluate whether use of neuraxial labor analgesia can reduce the incidence of postpartum depression.

NCT ID: NCT02789410 Completed - Clinical trials for Analgesia, Obstetrical

Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery

Start date: May 2016
Phase: N/A
Study type: Interventional

Intrathecal (IT) opioids are commonly administered with local anesthetic during spinal anesthesia for post-Cesarean delivery analgesia. Traditionally, IT morphine has been used but the use of IT hydromorphone is growing. A previous study has shown that the effective dose for postoperative analgesia in 90% patients (ED90) for both IT hydromorphone and IT morphine (NCT02009722). These doses were found to be 75 mcg for hydromorphone and 150 mcg for morphine. The current proposed study would compare the duration of analgesia of IT morphine vs IT hydromorphone after elective cesarean delivery. Additionally, the investigators will compare each drug with respect the incidence of nausea and pruritus.

NCT ID: NCT02509312 Completed - Postoperative Pain Clinical Trials

Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery

Start date: May 2016
Phase: Phase 4
Study type: Interventional

In this randomized, double-blind control trial to evaluate the effect of ketorolac given at the time of cord clamp has on estimated blood loss and postcesarean pain control. Patients will be randomized to either placebo or ketorolac prior to surgery. Those randomized to ketorolac will receive ketorolac at cord clamp and three additional doses every 6 hours (total 4 doses/24 hours). Those in the placebo group will receive normal saline during those time periods. Our primary outcome is to assess whether intra-operative ketorolac increases the estimated blood loss during Cesarean delivery.

NCT ID: NCT02009722 Completed - Cesarean Section Clinical Trials

Intrathecal Opioids for Pain Control After Cesarean Delivery: Determining the Optimal Dose

Start date: January 2014
Phase: Phase 4
Study type: Interventional

Both hydromorphone and morphine are administered as part of spinal anesthesia to help improve pain control after cesarean delivery. In this study, the investigators are going to determine the doses of each of those medicines that provides optimal pain control to women undergoing cesarean delivery while limiting side effects related to those medicines. The investigators hypothesize that the doses of hydromorphone and morphine that provide optimal pain control without significant side effects will be 100 micrograms and 150 micrograms, respectively. The investigators further hypothesize that at each respective optimal dose, side effects will be less in the hydromorphone group.